| Abstract: Four organotin 4-biphenylacetates, {[(n-C4H9)4Sn(O2CCH2C6H4C6H5-4)]2O}2 (1) and R3SnO2CCH2C6H4C6H5-4(R=C4H5，2；c-C6H11，3；C6H5C(CH3)2CH2，4), have been prepared and characterized by elemental analysis, IR, 1H and 13C NMR spectroscopes. The crystal structures of 1 and 4 have been determined. The crystal of 1 belongs to triclinic space group P1 with a=1.281(2) nm, b=1.379(2) nm, c=1.447(2) nm, α=76.15(2)°, β=65.47(2)°, γ=69.78(2)°, Z=1, V=2.168(4) nm3, R1=0.036 6, wR2=0.115 2. The crystal of 4 belongs to triclinic space group P1 with a=1.052(1) nm, b=1.128(1) nm, c=1.847(2) nm, α=75.45(1)°, β=74.94(1)°, γ=64.19(1)°, Z=2, V=1.880(3) nm3, R1=0.029 5, wR2=0.072 0. The compound 1 has a centrosymmetric dimmer structure with a four-membered cyclic Sn2O2 unit, and the compound 4 possesses a distorted tetrahedral structure. Bioassay results have shown that the compounds display good in vitro antitumor activity against three human tumour cell lines, HeLa, CoLo205 and MCF-7. CCDC: 250637, 1; 608675, 4. |
